INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.

ABSTRACT:

Background

Immunotherapies targeting immune checkpoint inhibitors have revolutionized cancer treatment but are limited by incomplete patient responses. Costimulatory agonists like OX40 (CD134), a tumor necrosis factor receptor family member critical for T-cell survival and differentiation, have shown preclinical promise but limited clinical success due to suboptimal receptor activation. Conventional bivalent OX40 agonists fail to induce the trimeric engagement required for optimal downstream signaling. To address this, we developed INBRX-106, a hexavalent OX40 agonist designed to enhance receptor clustering independently of Fc-mediated crosslinking and boost antitumor T-cell responses.

Methods

We assessed INBRX-106's effects on receptor clustering, signal transduction, and T

SUBMITTER: Holay N 

PROVIDER: S-EPMC12097044 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature